Adverse effects of ‘psychiatric medications’: Critical analysis with a focus on antidepressants

All psychoactive substances work by causing dysfunctions of the brain and mind--Peter R. Breggin, MD

Psychiatric medications, particularly antidepressants, are widely prescribed under the assumption that they correct underlying biochemical imbalances and alleviate mental suffering. Decades of clinical experience, controlled trials, regulatory data, and forensic analyses demonstrate otherwise. These substances do not heal; they produce brain dysfunction. This report synthesizes evidence from my research and publications on the dangers of these interventions, including stimulation/activation syndromes, suicidality, violence, mania, chronic brain impairment, and medication spellbinding.

I have called on therapists and healthcare providers and clients to have a more rational understanding of how psychiatric drugs actually “work.”

“Because the epidemic dispensing of psychiatric drugs is based on misinformation, it is important for all health professionals, consumers, and most citizens (including patients and their family members) to have a more rational understanding of how psychiatric drugs actually ‘‘work.’’ Instead of enforcing authoritarian ‘‘medication compliance’’ in obedience to the prescriber’s orders, informed therapists and healthcare providers have an ethical duty to provide scientific information about the real effects of psychiatric drugs. Instead of naively accepting whatever the doctor prescribes to them, consumers need to educate themselves about all medications, but especially about psychiatric ones, which are consistently misrepresented and oversold.” — Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients (2016)

The Brain-Disabling Principle of Psychiatric Drugs

“All psychoactive substances work by causing dysfunctions of the brain and mind. It further observes that no psychiatric drugs work by improving or correcting biochemical imbalances or any other presumed biological malfunctions.” — Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients (2016)

All psychoactive medications exert their primary effects by disabling normal brain function rather than correcting hypothetical defects. This principle, elaborated in Brain-Disabling Treatments in Psychiatry (Breggin, 2008), applies across drug classes. Antidepressants, for instance, disrupt serotonin neurotransmission in ways that initially produce sedation or activation but lead to broader compensatory changes and long-term impairments.

Long-term exposure results in Chronic Brain Impairment (CBI), a syndrome characterized by cognitive deficits, emotional blunting, apathy, and persistent brain dysfunction that can mimic or exacerbate dementia-like states. This is documented in my 2011 paper, “Psychiatric drug-induced Chronic brain Impairment (CBI): Implications for long-term treatment with psychiatric medication,” and aligns with observations of brain atrophy and lasting disability following prolonged use. Similar patterns occur with antipsychotics, benzodiazepines, and stimulants.

Activation (Stimulation) Syndromes Induced by Antidepressants

“The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants... These reactions are especially dangerous in vulnerable populations.” — Recent Regulatory Changes in Antidepressant Labels: Implications of Activation (Stimulation) for Clinical Practice (2006)

A central hazard of selective serotonin reuptake inhibitors (SSRIs) and related antidepressants is their propensity to cause activation or overstimulation. This cluster includes anxiety, agitation, insomnia, irritability, hostility, impulsivity, akathisia (severe restlessness), hypomania, and mania. These effects are explicitly acknowledged in FDA-mandated warnings.

In clinical practice, this stimulation can rapidly escalate. My case report on fluoxetine illustrates how energizing effects, insomnia, and compulsive behaviors can precede a “crash” and profound distress. Similar patterns appear with fluvoxamine, paroxetine, and other agents.

These reactions are especially dangerous in vulnerable populations. In military personnel, antidepressant-induced activation can mimic or worsen PTSD symptoms, increasing risks under combat stress or during reintegration.

Suicidality, Violence, and Mania

“Evidence from many sources confirms that selective serotonin reuptake inhibitors (SSRIs) commonly cause or exacerbate a wide range of abnormal mental and behavioral conditions. These adverse drug reactions include... a stimulant profile that ranges from mild agitation to manic psychoses, agitated depression, obsessive preoccupations... and akathisia. Each of these reactions can worsen the individual’s mental condition and can result in suicidality, violence, and other forms of extreme abnormal behavior.” — Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis (2004)

SSRIs commonly cause or exacerbate suicidality, violence, and manic states. My comprehensive review compiles clinical reports, trials, and epidemiological data confirming these overlapping phenomena. Akathisia and obsessive preoccupations alien to the individual’s character frequently drive these outcomes.

Analyses of GlaxoSmithKline’s internal data on Paxil (paroxetine), drawn from product liability cases, reveal suppressed evidence on akathisia, stimulation, and suicidality. Meta-analyses later confirmed elevated risks in adults, particularly young adults, consistent with my earlier findings. Comparable issues exist with fluvoxamine and other SSRIs.

These risks extend beyond depression treatment. My editorial, “From Prozac to Ecstasy: The Implication of New Evidence for Drug-Induced Brain Damage” highlights parallels in brain-damaging effects between certain antidepressants and illicit stimulants, underscoring societal underestimation of pharmaceutical harms.

Intoxication Anosognosia (Medication Spellbinding)

“All psychoactive substances tend to cause a subjective over-estimation of their positive effects while masking their harmful ones, sometimes resulting in extremely harmful behaviors such as mania, violence and suicide.” — Intoxication anosognosia: The spellbinding effect of psychiatric drugs (2007)

A particularly insidious effect is intoxication anosognosia, or medication spellbinding, whereby individuals overestimate benefits while remaining unaware of harmful changes in their mental state or behavior. This phenomenon explains continued use despite emerging mania, violence, or cognitive decline. It contributes to tragic outcomes in forensic cases and everyday clinical practice.

Broader Context: The Psychopharmaceutical Complex and Historical Parallels

“The violence initiative exemplifies the political use of biological psychiatry... If it fails to fully materialize, the violence initiative will stand as a warning about the dangers inherent in approaching social problems from a biopsychiatric, medical or public health orientation.” — A biomedical programme for urban violence control in the US: the dangers of psychiatric social control (with Ginger Ross Breggin, 1993)

The dominance of biological psychiatry and pharmaceutical influence fosters over-reliance on drugs while marginalizing psychosocial approaches. The proposed “Violence Initiative” of the early 1990s exemplifies the dangers of biopsychiatric social control targeting vulnerable populations.

Medication Madness (Breggin, 2008) and Psychiatric Drug Withdrawal (Breggin, 2013) provide extensive case studies and guidance for safer deprescribing, emphasizing that drugs often do more harm than good. *Rational Principles of Psychopharmacology* advocates informed consent, recognition of brain-disabling effects, and prioritization of empathic, non-drug therapies.

Implications and Recommendations

Psychiatric medications, especially antidepressants, carry substantial risks of stimulation, suicidality, violence, chronic impairment, and spellbinding effects. These are not rare idiosyncrasies, but predictable outcomes rooted in brain-disabling pharmacology. Regulatory warnings, though improved, remain insufficiently emphasized in practice.

Clinicians must monitor closely for activation signs, prioritize lowest effective doses for shortest durations (or avoid where possible), and support withdrawal when harms emerge. Patients and families deserve full disclosure. Proven psychosocial interventions—empathic therapy, counseling, lifestyle changes, and community support—offer safer, more effective paths to recovery.

The epidemic of psychiatric drugging demands greater skepticism toward the psychopharmaceutical complex. Greater awareness, rigorous science, and a return to humane, non-drug approaches are essential to protect individual patient wellbeing and public health.

By Peter R. Breggin, M.D.

Psychiatrist in Private Practice

Ithaca, New York

References

1. Breggin, P.R., & Breggin, G.R. (1993). A biomedical programme for urban violence control in the US: the dangers of psychiatric social control. Ethical Human Sciences and Services.

2. Breggin, P.R. (2014). Chapter 10: TBI, PTSD, and Psychiatric Drugs: A Perfect Storm for Causing Abnormal Mental States and Aberrant Behavior. In The Attorney’s Guide to Defending Veterans in Criminal Court (Brockton D. Hunter & Ryan C. Else, Eds.). Veterans Defense Project.

3. Breggin, P.R. (2001). From Prozac to Ecstasy: The Implication of New Evidence for Drug-Induced Brain Damage. Ethical Human Sciences and Services, 3(1).

4. Breggin, P.R. (2016). Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients. Journal of Contemporary Psychotherapy, 46(1), 1-13.

5. Breggin, P.R. (2006). Drug Company Suppressed Data on Paroxetine-Induced Stimulation: Implications for Violence and Suicide (Paxil Special Report III). Ethical Human Psychology and Psychiatry, 8(3).

6. Breggin, P.R. (1992). A case of fluoxetine-induced stimulant side effects with suicidal ideation associated with a possible withdrawal reaction (”crashing”). International Journal of Risk & Safety in Medicine.

7. Breggin, P.R. (2006). Recent Regulatory Changes in Antidepressant Labels: Implications of Activation (Stimulation) for Clinical Practice. Primary Psychiatry, 13(1), 57-60.

8. Breggin, P.R. (2004). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. International Journal of Risk & Safety in Medicine, 16.

9. Breggin, P.R. (2006). Recent Regulatory Changes in Antidepressant Labels (CME version). Primary Psychiatry.

10. Breggin, P.R. (2004). Recent U.S., Canadian and British regulatory agency actions concerning antidepressant-induced harm to self and others: A review and analysis. International Journal of Risk & Safety in Medicine, 16.

11. Breggin, P.R. (2001). Fluvoxamine as a cause of stimulation, mania and aggression with a critical analysis of the FDA-approved label. International Journal of Risk & Safety in Medicine, 14.

12. Breggin, P.R. (2006). How GlaxoSmithKline Suppressed Data on Paxil-Induced Akathisia: Implications for Suicidality and Violence (Paxil Special Report II). Ethical Human Psychology and Psychiatry, 8(2).

13. Breggin, P.R. (2006). Court Filing Makes Public My Previously Suppressed Analysis of Paxil’s Effects (Paxil Special Report I). Ethical Human Psychology and Psychiatry, 8(1).

14. Breggin, P.R. (2007). Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International Journal of Risk & Safety in Medicine, 19.

15. Breggin, P.R. (2010). Antidepressant-Induced Suicide, Violence, and Mania: Risks for Military Personnel. Ethical Human Psychology and Psychiatry, 12(2).

16. Breggin, P.R. (2011). Psychiatric drug-induced Chronic Brain Impairment (CBI): Implications for long-term treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23.

17. Dr. Peter Breggin’s Antidepressant Drug Resource and Information Center:

List of Antidepressants

Scientific Articles by Category

Key Books

- Breggin, P.R. (2008). Medication Madness: The Role of Psychiatric Drugs in Cases of Violence, Suicide and Crime.

- Breggin, P.R. (2013). Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients and Their Families.

- Breggin, P.R. (2008). Brain-Disabling Treatments in Psychiatry.

- Breggin, P.R., & Breggin, G.R. (1994). Talking Back to Prozac.

- Breggin, P.R. (1991). Toxic Psychiatry.

WARNING: Psychiatric drugs are not only dangerous to take, they are also dangerous to withdraw from. Withdrawal from psychiatric drugs should be done cautiously with professional supervision. Please see the book by Peter R. Breggin, MD, Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients and their Families. This report draws directly from the cited works and aims to inform professionals, patients, and policymakers. For consultations or further resources, visit www.breggin.com.